Raj N. Sewduth
Leuven, VLG 3000, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Molecular Design of Novel Protein-Degrading Therapeutics Agents Currently in Clinical Trial.
Journal: Pharmaceutics
Published: April 16, 2025
Intrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation.
Journal: Nature communications
Published: November 12, 2024
Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective.
Journal: Journal of xenobiotics
Published: November 11, 2024
Recent Advances in Peptide Drug Discovery: Novel Strategies and Targeted Protein Degradation.
Journal: Pharmaceutics
Published: October 01, 2024
Multi-Omic Approaches in Cancer-Related Micropeptide Identification.
Journal: Proteomes
Published: July 31, 2024
Relevance of Carcinogen-Induced Preclinical Cancer Models.
Journal: Journal of xenobiotics
Published: November 15, 2023
K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins.
Journal: The EMBO journal
Published: October 17, 2023
Spatial Mechano-Signaling Regulation of GTPases through Non-Degradative Ubiquitination.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 25, 2023
Targeted STAT1 therapy for LZTR1-driven peripheral nerve sheath tumor.
Journal: Cancer communications (London, England)
Published: May 09, 2023
Novel Therapeutic Approaches Targeting Post-Translational Modifications in Lung Cancer.
Journal: Pharmaceutics
Published: December 12, 2022
Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development.
Journal: Cancer research
Published: November 01, 2020
Last Updated: 09/26/2026